Literature DB >> 17927580

Expression of tumour necrosis factor-related apoptosis-inducing ligand and caspase-3 in relation to grade of inflammation and stage of fibrosis in chronic hepatitis C.

A Piekarska1, R Kubiak, A Omulecka, W Szymczak, J Piekarski.   

Abstract

AIM: To assess whether the distribution of the recently described proapoptotic ligand, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), and the apoptosis effector, caspase-3 alters with the degree of inflammation and fibrosis present in liver biopsy specimens from patients with chronic hepatitis C virus infection. METHODS AND
RESULTS: Expression of TRAIL and caspase-3 was assessed immunohistochemically in liver biopsy specimens obtained from 89 adults with chronic hepatitis C. Expression of TRAIL in hepatocytes correlated inversely with stage of fibrosis (P = 0.001), classified according to the Scheuer score; expression of caspase-3 in hepatocytes correlated with grade of inflammation (P = 0.012). Expression of TRAIL in hepatocytes was not correlated with grade of inflammation (P > 0.05); expression of caspase-3 was not correlated with stage of fibrosis (P > 0.05). Maximum expression of proapoptotic TRAIL protein was observed in cases with low grade inflammation (G0) and low stage fibrosis (S1). Maximum expression of caspase-3 in hepatocytes was observed in cases with high grade inflammation (G3-4) and high stage fibrosis (S3), but not with liver cirrhosis (S4).
CONCLUSIONS: There is a significant decrease in TRAIL expression with increasing grade of inflammation, whereas caspase-3 expression is significantly increased with advanced fibrosis, short of cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17927580     DOI: 10.1111/j.1365-2559.2007.02863.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  3 in total

1.  Soluble TRAIL levels decreased in chronic hepatitis C treatment with pegylated interferon α plus ribavirin: association with viral responses.

Authors:  Derya Seyman; Arzu Didem Yalcin; Nefise Oztoprak; Gizem Esra Genc; Nevgun Sepin Ozen; Filiz Kizilates; Hande Berk; Saadet Gumuslu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  Caspase inhibitors for the treatment of hepatitis C.

Authors:  Howard C Masuoka; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Clin Liver Dis       Date:  2009-08       Impact factor: 6.126

3.  Low doses of the novel caspase-inhibitor GS-9450 leads to lower caspase-3 and -8 expression on peripheral CD4+ and CD8+ T-cells.

Authors:  J E Arends; A I M Hoepelman; N M Nanlohy; F J P Höppener; K R Hirsch; J G Park; D van Baarle
Journal:  Apoptosis       Date:  2011-09       Impact factor: 4.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.